Table of Content

1. Product Overview
2. Research Methodology
3. Impact of COVID-19 on United Kingdom Pharmaceutical Market
4. Executive Summary
5. Voice of Customer
6. United Kingdom Pharmaceutical Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Drug Type (Generic Drugs v/s Branded Drugs)
6.2.2. By Product Type (Prescription Drugs v/s Over-The-Counter Drugs)
6.2.3. By Application (Cardiovascular, Musculoskeletal, Oncology, Anti-infective, Metabolic Disorder, Others)
6.2.4. By Distribution Channel (Retail Pharmacy, Hospital Pharmacy, E-Pharmacy)
6.2.5. By Region
6.2.6. By Company (2021)
6.3. Product Market Map
7. United Kingdom Generic Drugs Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Product Type
7.2.2. By Application
7.2.3. By Distribution Channel
8. United Kingdom Branded Drugs Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Product Type
8.2.2. By Application
8.2.3. By Distribution Channel
9. Market Dynamics
9.1. Drivers
9.2. Challenges
10. Market Trends & Developments
11. Policy & Regulatory Landscape
12. United Kingdom Economic Profile
13. Competitive Landscape
13.1. Takeda Pharmaceutical Company Limited
13.2. GlaxoSmithKline Plc.
13.3. Vertex Pharmaceuticals (U.K.) Limited
13.4. Pfizer Limited
13.5. Novartis UK Limited
13.6. AstraZeneca UK Limited
13.7. Bristol-Myers Squibb Pharmaceuticals Limited
13.8. Roche Products Limited
13.9. Sanofi UK
13.10. Sun Pharmaceuticals UK Limited
14. Strategic Recommendations